Why Ubiquinol Demand Is Rising After the First Mitochondrial Health Summit

The inaugural Mitochondrial Health Summit in Sydney last week did not just gather researchers. It marked a shift in how a growing part of the supplement industry frames its pitch: less about energy, more about the cellular mechanism itself. For Kaneka, the sole global manufacturer of bioidentical Ubiquinol, the timing matters.

Kaneka sponsored the summit and used it to reinforce a category it calls "mitoceuticals" – supplements targeting mitochondrial function directly. Tsuyoshi Takakuwa, head of Kaneka's APAC supplemental nutrition division, said the company believes mitochondrial health "will become one of the defining healthcare conversations of the next decade." The summit faculty included cardiologists, reproductive health specialists, and pharmacists, reflecting a push beyond the traditional supplement aisle into clinical settings.

Ubiquinol is the reduced, antioxidant-active form of CoQ10. Levels decline naturally after age 20. Kaneka holds 80+ patents on its fermentation process and supplies the ingredient to more than 1,000 brands across 50 countries. The company's manufacturing certifications include HALAL, GRAS, HACCP, and Non-GMO – a compliance stack that matters for institutional buyers and pharmacy chains.

The read-through for the supplement sector is not uniform. Kaneka's position as sole manufacturer of bioidentical Ubiquinol gives it pricing power that most ingredient suppliers lack. Competitors in the broader CoQ10 space – including DSM-Firmenich and a handful of Chinese manufacturers – offer ubiquinone (the oxidized form) but not the bioidentical reduced form. That distinction matters for brands targeting the clinical channel, where doctors are more likely to recommend the form with published human trials.